$IMUC
EOM Pharmaceutical Holdings, Inc.

2018 Q3 Form 10-Q Financial Statement

#000082241118000009 Filed on August 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2018 Q2 2017 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $670.2K $1.108M
YoY Change -32.18% -43.16%
% of Gross Profit
Research & Development $58.98K -$676.7K
YoY Change -99.43% -112.6%
% of Gross Profit
Depreciation & Amortization $100.00 $640.00
YoY Change -99.4% -96.8%
% of Gross Profit
Operating Expenses $307.1K $431.7K
YoY Change -97.29% -94.1%
Operating Profit -$307.1K
YoY Change -97.29%
Interest Expense $0.00 $400.00
YoY Change -100.0% -99.96%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$306.7K -$431.3K
YoY Change -92.43% -93.18%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$306.7K -$431.3K
YoY Change -92.43% -93.18%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$73.17K -$123.1K
COMMON SHARES
Basic Shares Outstanding 41.93M shares 41.93M shares 35.20M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2018 Q2 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.853M $6.630M
YoY Change 57.25% -42.05%
Cash & Equivalents $2.853M $6.630M
Short-Term Investments
Other Short-Term Assets $489.7K $378.8K
YoY Change -81.09% -52.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.829M $7.009M
YoY Change -13.04% -47.75%
LONG-TERM ASSETS
Property, Plant & Equipment $356.00 $568.00
YoY Change -99.54% -99.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change -100.0%
Total Long-Term Assets $356.00 $568.00
YoY Change -99.91% -99.98%
TOTAL ASSETS
Total Short-Term Assets $3.829M $7.009M
Total Long-Term Assets $356.00 $568.00
Total Assets $3.829M $7.009M
YoY Change -20.4% -58.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $84.26K $1.775M
YoY Change -98.02% 32.22%
Accrued Expenses $161.5K $295.6K
YoY Change -95.06% -62.44%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $401.9K $2.361M
YoY Change -94.79% -27.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $401.9K $2.361M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $401.9K $2.361M
YoY Change -94.81% -78.06%
SHAREHOLDERS EQUITY
Retained Earnings -$117.8M -$116.4M
YoY Change 11.47% 21.01%
Common Stock $121.2M $121.1M
YoY Change 17.99% 18.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.427M $4.648M
YoY Change
Total Liabilities & Shareholders Equity $3.829M $7.009M
YoY Change -20.4% -58.5%

Cashflow Statement

Concept 2018 Q3 2018 Q2 2017 Q4
OPERATING ACTIVITIES
Net Income -$306.7K -$431.3K
YoY Change -92.43% -93.18%
Depreciation, Depletion And Amortization $100.00 $640.00
YoY Change -99.4% -96.8%
Cash From Operating Activities -$2.174M -$4.929M
YoY Change -37.04% 31.79%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 5.553M
YoY Change -100.0% -4727.87%
NET CHANGE
Cash From Operating Activities -2.174M -4.929M
Cash From Investing Activities 0.000
Cash From Financing Activities 0.000 5.553M
Net Change In Cash -2.174M 624.6K
YoY Change -38.29% -116.18%
FREE CASH FLOW
Cash From Operating Activities -$2.174M -$4.929M
Capital Expenditures $0.00
Free Cash Flow -$4.929M
YoY Change 31.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Period End Date
DocumentPeriodEndDate
2018-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000822411
CY2018Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41934984 shares
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Entity Registrant Name
EntityRegistrantName
ImmunoCellular Therapeutics, Ltd.
dei Trading Symbol
TradingSymbol
IMUC
imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
-0.08
imuc Change In Fair Value Of Warrant Liability For Income Taxes
ChangeInFairValueOfWarrantLiabilityForIncomeTaxes
0.00
imuc Debt Reclassified To Accrued Liabilities
DebtReclassifiedToAccruedLiabilities
108984 USD
imuc Debt Reclassified To Accrued Liabilities
DebtReclassifiedToAccruedLiabilities
0 USD
imuc Deposits Reclassified To Other Current Assets
DepositsReclassifiedToOtherCurrentAssets
1922218 USD
imuc Deposits Reclassified To Other Current Assets
DepositsReclassifiedToOtherCurrentAssets
0 USD
imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
89726 USD
imuc Financing Costs Incurredbut Notyet Paid
FinancingCostsIncurredbutNotyetPaid
0 USD
imuc Supplies Write Off
SuppliesWriteOff
2349404 USD
imuc Supplies Write Off
SuppliesWriteOff
0 USD
CY2018Q2 imuc Working Capital
WorkingCapital
3427092 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1774626 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
84256 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
295612 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
161461 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16339 USD
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16551 USD
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
121087939 USD
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
121198601 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1724515 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1850340 shares
CY2017Q4 us-gaap Assets
Assets
7009225 USD
CY2018Q2 us-gaap Assets
Assets
3829392 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
7008657 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
3829036 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11437118 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1814005 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6629870 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2852605 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9623113 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3777265 USD
CY2017Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
466875 USD
CY2018Q2 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
467477 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41913256 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41913256 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41913256 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41913256 shares
CY2018Q2 us-gaap Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
3267871 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
4191 USD
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
4191 USD
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
851633 USD
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1223724 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2251184 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2282169 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3102817 USD
CY2018Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
3505893 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0 USD
us-gaap Depreciation
Depreciation
33190 USD
us-gaap Depreciation
Depreciation
212 USD
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.81
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.03
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.12
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.28
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.20
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.00
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.06
us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.07
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
290516 USD
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
156227 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P9M
CY2018Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
113758 USD
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0 USD
CY2017Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
7719440 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
7719440 USD
CY2018Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
988266 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1781444 USD
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
670203 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1404784 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4052070 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9979833 USD
CY2018Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-306704 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1331685 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2018Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2843974 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1690370 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2346767 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-134151 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-908221 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-134289 USD
us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
0 USD
us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
486774 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
882683 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-157967 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
110870 USD
us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
-146430 USD
us-gaap Increase Decrease In Prepaid Supplies
IncreaseDecreaseInPrepaidSupplies
0 USD
CY2018Q2 us-gaap Insurance Recoveries
InsuranceRecoveries
422094 USD
CY2017Q4 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
0 USD
CY2018Q2 us-gaap Insurance Settlements Receivable Current
InsuranceSettlementsReceivableCurrent
486774 USD
CY2017Q2 us-gaap Interest Expense
InterestExpense
430024 USD
us-gaap Interest Expense
InterestExpense
882683 USD
CY2018Q2 us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
381 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
4175 USD
CY2018Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
386 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
602 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7009225 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-99929 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3829392 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2360754 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
401944 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9523184 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3777265 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-4052070 USD
us-gaap Net Income Loss
NetIncomeLoss
-9979833 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-306704 USD
us-gaap Net Income Loss
NetIncomeLoss
-1331685 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
11341867 USD
us-gaap Operating Expenses
OperatingExpenses
16820765 USD
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
307090 USD
us-gaap Operating Expenses
OperatingExpenses
1332287 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-11341867 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-16820765 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-307090 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-1332287 USD
CY2018Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4400000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
378787 USD
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
489657 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
140929 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2 shares
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
2 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
41000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16907 USD
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
16907 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
568 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
356 USD
CY2017Q2 us-gaap Recovery Of Direct Costs
RecoveryOfDirectCosts
0 USD
CY2018Q2 us-gaap Recovery Of Direct Costs
RecoveryOfDirectCosts
422094 USD
us-gaap Recovery Of Direct Costs
RecoveryOfDirectCosts
422094 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10353601 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15039321 USD
CY2018Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58981 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
349597 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116443659 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117775344 USD
CY2017Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
CY2018Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
323895 USD
us-gaap Share Based Compensation
ShareBasedCompensation
110662 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3925 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
91656 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y1M16D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
110662 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
4648471 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
3427448 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2018Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
870200 USD
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
403076 USD
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3551575 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3550550 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41913256 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
41913256 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
87731 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.31
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
40.28
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
74205 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
44.18
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.00
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
87.78
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates </font><font style="font-family:inherit;font-size:10pt;">&#8211; The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make certain estimates and assumptions about the future outcome of current transactions, which may affect the reporting and disclosure of these transactions. Accordingly, actual results could differ from those estimates used in the preparation of these condensed consolidated financial statements.</font></div></div>

Files In Submission

Name View Source Status
0000822411-18-000009-index-headers.html Edgar Link pending
0000822411-18-000009-index.html Edgar Link pending
0000822411-18-000009.txt Edgar Link pending
0000822411-18-000009-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
imuc-20180630.xml Edgar Link completed
imuc-20180630.xsd Edgar Link pending
imuc-20180630_cal.xml Edgar Link unprocessable
imuc-20180630_def.xml Edgar Link unprocessable
imuc-20180630_lab.xml Edgar Link unprocessable
imuc-20180630_pre.xml Edgar Link unprocessable
imuc-63018x10q.htm Edgar Link pending
imuc-63018xexhibit101.htm Edgar Link pending
imuc-63018xexhibit311.htm Edgar Link pending
imuc-63018xexhibit312.htm Edgar Link pending
imuc-63018xexhibit321.htm Edgar Link pending
imuc-63018xexhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending